Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokKorai 1. fázis

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

A legfontosabb adatok

Ki végzi
Virginia Clinical Research, Inc.
Hol
Norfolk (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
15 fő, tervezett
Kezdés
2024. dec. 3.
Tervezett befejezés
2025. máj.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • EVO101
A regiszteradat frissítve
2024. december 11.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with mild to moderate hidradenitis suppurativa (HS), a long-lasting skin disease with painful lumps. Participants apply EVO101 cream 0.1% for 12 weeks.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
HS diagnosed at least 3 months before screening. Mild to moderate HS on the HS-PGA doctor's scale, with at least 5 HS lesions (abscesses, tunnels, nodules, papules or pustules).
Korábbi kezelés
No antibiotic creams or pills for HS during the study. No bleach baths or chlorhexidine gluconate or benzoyl peroxide washes. Many earlier treatments must be stopped for a set time before the start, for example biologic drugs (12 weeks), JAK inhibitors and immunosuppressants (4 weeks), and creams on HS lesions (1 week).

A részvétel fő kizáró okai

  • Very severe, severe, minimal or clear HS
  • Pregnant, planning pregnancy, or breastfeeding
  • Serious injury or major surgery within 30 days before screening
  • Serious drug or alcohol abuse within 6 months before screening
  • In another experimental therapy study, or had experimental therapy within 30 days or 5 half-lives before the start

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study
  • Age ≥ 18 years at the time of signing the ICF (informed consent)
  • Diagnosis of hidradenitis suppurativa (HS) for at least 3 months prior to the screening visit
  • Mild to moderate HS (hidradenitis suppurativa) at the Baseline Visit (using the HS-PGA/Hidradenitis Suppurativa Physician's Global Assessment scale )
  • Total hidradenitis suppurativa lesion count (abscess, fistulas, nodules, papules, and/or pustules) of at least 5 at the baseline visit
  • Agreement to NOT use topical and/or systemic antibiotics for treatment of HS (hidradenitis suppurativa) for the duration of the study
  • Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide. Note: Over-the-counter non-medicated soap and water is allowed
  • For women of childbearing potential: agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 30 days after the last application of study drug; A woman of childbearing potential is defined as a postmenarcheal female, who has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus); The following are highly effective contraceptive methods: combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation, progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, or sexual abstinence. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. Females must agree not to donate ova during the study and for 30 days after the end of study visit
  • Willing and able to comply with the study protocol and procedures

Ki nem vehet részt

  • Have undergone significant trauma or major surgery (per investigator's assessment) within 30 days preceding the screening visit
  • Use of any of the following medications or treatments within the specified time periods prior to the baseline visit:; < 12 weeks or 5 half-lives (whichever is longer); Investigational or experimental treatments; Immunomodulating biologic drugs; < 4 weeks; Systemic JAK inhibitors; Systemic immunosuppressive or immunomodulating small-molecule drugs (eg, corticosteroids [oral or intravenous], avacopan, IRAK4 inhibitors, methotrexate, cyclosporine, dapsone, azathioprine); Surgical, laser, or any phototherapy intervention in areas with HS lesions; < 2 weeks; Other systemic therapies for HS; Retinoids, antihyperglycemics, and antiandrogens, such as acitretin, isotretinoin, metformin, spironolactone, and finasteride) with potential therapeutic impact unless the subject is on a stable dose as defined by the investigator for at least 28 days. There should be no anticipated change of these medications while the subject is on the study; Systemic anti-infectives for HS; Antibiotics, antivirals, antifungals; <1 week; Oral or topical PDE4 inhibitor (e.g., apremilast, crisaborole); Topical JAK inhibitor; Topical anti-infectives for HS lesions; o Antibiotics, antivirals, antifungals; Topical products containing chlorhexidine gluconate, benzoyl peroxide, or topical diluted bleach bath to treat HS. Note: Non-medicated over-the-counter soap and water are not restricted; Any topical drug applied onto HS lesions; Topical or intralesional corticosteroids o Note: Use of topical corticosteroids for dermatologic diseases other than HS (Hidradenitis Suppurativa)(e.g., atopic dermatitis, psoriasis) is allowed for areas not being treated for HS (Hidradenitis Suppurativa)as long as it is not within 10cm of the areas affected by HS (Hidradenitis Suppurativa); Inhaled corticosteroids are allowed
  • Active participation in an experimental therapy study or who received experimental therapy within 30 days or 5 half-lives (whichever is longer) before Baseline
  • History of clinically significant (per investigator's judgment) drug or alcohol abuse within 6 months preceding the screening visit
  • Very severe, severe, minimal, or clear hidradenitis suppurativa Hidradenitis Suppurativa Physician's Global Assessment scale (HS-PGA)
  • Women who are pregnant (or who are considering pregnancy) or breastfeeding
  • Subject has uncontrolled, clinically significant comorbidities that make them unsuitable for the clinical trial in the opinion of the investigator

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Virginia Clinical Research, Inc.Norfolk, Egyesült ÁllamokContact: Danielle BenedictRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit.

What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires.

Participants will:

Apply EVO101 topical cream 0.1% topically Visit the clinic four times unless the first and second appointment have to be done separately then there will be five clinic visits and one phone call over a twelve week period.

Keep a dosing diary

A vizsgálat csoportja

  • Open label EVO101 topical cream 0.1%A vizsgált kezelés

    All eligible subjects will receive open label EVO101 topical cream 0.1%

    Kezelés: EVO101

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Open-label, Investigator-initiated, Single-site Proof of Concept Trial Evaluating EVO101 in Adult Subjects with Mild to Moderate Hidradenitis Suppurativa.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2024. december 11.